Priya cmi (4)

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
TOXOPLASMOSIS TREATMENT DRUGS MARKET ANALYSIS

• Toxoplasmosis Treatment Drugs Market, by
  Indication (Chronic Toxoplasmosis Infection, and
  Acute Toxoplasmosis Infection), by Route of
  Administration ( Parental Route and Oral Route),
  by Drug Class (Pyrimethamine, Spiramycin,
  Leucovorin, Sulfadiazine, Clindamycin, Zithromax,
  Mepron, Clarithromycin, and Others), by
  Distribution Channel (Hospital Pharmacies, Online
  Pharmacies and Retail Pharmacies), and by Region
  (North America, Latin America, Europe, Middle
  East, Asia Pacific, and Africa) - Size, Share,
  Outlook, and Opportunity Analysis, 2020 - 2027

3

• Global Toxoplasmosis Treatment Drugs
  Market Drivers
• The global toxoplasmosis treatment drugs market
  is expected to witness significant growth during
  the forecast period as pharmaceutical companies
  are focusing on research and development of
  treatments for toxoplasmosis. For instance, in
  2018, Vyera Pharmaceuticals LLC received the U.S.
  Food Drug and Administration (FDA) clearance to
  initiate Phase 1 study of the VYR-006, which is a
  potent dihydrofolate reductase (DHFR) inhibitor
  used for treatment of toxoplasmosis.
• Moreover, the growing prevalence of HIV across
  the globe is increasing risk of toxoplasma gonad
  infection due to less immune response in HIV
  infected patients. For instance, according to the
  World Health Organization (WHO), by the end of
  2018, around 37.9 million people across the globe
  had HIV, therefore it is expected to increase
  prevalence of toxoplasmosis infection among the
  global population.

4
Global Toxoplasmosis Treatment Drugs COVID-19
Impact Analysis

• The COVID-19 pandemic has impacted growth of
  several markets across the globe and it is also
  expected to hamper the growth of the global
  toxoplasmosis treatment drugs market during the
  forecast period. Moreover, safety precautions
  suggested by the World Health Organization to
  reduce the spread of COVID-19 and implementation
  of nationwide lockdowns have affected the supply
  chain of toxoplasmosis treatment drugs due to
  higher shipping prices because of reduced
  excipient supply containers

5

• Global Toxoplasmosis Treatment Drugs
  Market Restraints
• The use of pyrimethanine and sulfadiazine drugs
  are characterized by side effects in pregnant
  women such as injury to the fetus and bone marrow
  suppression. Moreover, according to U.S. Food
  Drug and Administrations February 2020 report,
  the most common side effect of pyrimethamine is
  hypersensitivity, which leads to severe diseases
  such as Stevens-Johnson syndrome and toxic
  epidermal necrolysis. Furthermore, low dosage of
  promethazine can also cause hematologic effects
  in patients. These factors are expected to
  restrain growth of the global toxoplasmosis
  treatment drugs market.

6

• Global Toxoplasmosis Treatment Drugs
  Market Regional Analysis
• On the basis of region, the global toxoplasmosis
  treatment drugs market is segmented into North
  America, Latin America, Europe, Asia Pacific,
  Middle East, and Africa. In 2020, North America
  is expected to account the largest market share
  in the global toxoplasmosis treatment drugs
  market owing to factors such as the increasing
  prevalence of toxoplasmosis infection. According
  to the Centers for Disease Control and
  Preventions September 2018 report, in the U.S,
  around 11 of the population in the age group of
  6 or older suffered from toxoplasma.
• Furthermore, pharmaceutical companies are
  focusing on research and development of effective
  treatments for toxoplasmosis to strengthen their
  market share in the global toxoplasmosis
  treatment drugs market.  For instance, in
  February 2020, Cerovene Inc. obtained approval
  for generic Daraprim (pyrimethamine) tablet for
  treatment of toxoplasmosis from the U.S. FDA. The
  drug is used with combination of sulfonamide for
  treatment of toxoplasmosis bacterial infection.
• Europe is expected to witness significant growth
  in the global toxoplasmosis treatment drugs
  market due to the rising prevalence of HIV in
  Europe. For instance, according to the World
  Health Organizations 2018 report, over 2 million
  people in Europe were affected by HIV.
•  

7

• Global Toxoplasmosis Treatment Drugs Market Key
  Players
• Key players operating in the global toxoplasmosis
  treatment drugs market are Vyera Pharmaceuticals
  LLC, Taj Accura Pharmaceuticals Ltd, Mangalam
  Drugs and Organics Ltd., Cerovene Healthcare PVT
  LTD, Greenstone LLC, Amneal Pharmaceuticals,
  Inc., Turing Pharmaceuticals, F. Hoffmann-La
  Roche AG, Teva Pharmaceutical Industries Ltd, and
  Baxter International Inc.
• Market Taxonomy
• On the basis of indication, the global
  toxoplasmosis treatment drugs market is segmented
  into
• Chronic Toxoplasmosis Infection
• Acute Toxoplasmosis Infection

8

• On the basis of route of administration, the
  global toxoplasmosis treatment drugs market is
  segmented into
• Parental Route
• Oral Route
• On the basis of drug class, the global
  toxoplasmosis treatment drugs market is segmented
  into
• Pyrimethamine
• Spiramycin
• Leucovorin
• Sulfadiazine
• Clindamycin
• Zithromax
• Mepron
• Clarithromycin
• Others

9

• On the basis of distribution channel, the global
  toxoplasmosis treatment drugs market is segmented
  into
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• On the basis of region, the global toxoplasmosis
  treatment drugs market is segmented into
• North America
• Latin America
• Europe
• Middle East
• Asia Pacific
• Africa

10

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Buy Now
• Reference https//www.coherentmarketinsights.com/
  ongoing-insight/toxoplasmosis-treatment-drugs-mark
  et-4166

11
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

12
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

13

• Thank You!
• Kindly follow CMI Social Media
  Profiles for the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/